SRTSHIGH SIGNALFINANCIAL10-K

SRTS experienced a dramatic financial deterioration with revenue declining 34% and swinging from $8.1M operating income to a $10.3M operating loss.

The company's core business fundamentals have significantly weakened, with the massive drop in accounts receivable suggesting either collection issues or a sharp decline in recent sales activity. The simultaneous increase in R&D spending by 85% during a revenue decline period raises questions about capital allocation and cash management priorities.

Comparing 2026-03-04 vs 2025-03-05View on EDGAR →
FINANCIAL ANALYSIS

SRTS showed severe financial stress with revenue falling 34% to $27.5M while gross profit was cut in half to $11.9M, indicating margin compression beyond just volume decline. The company swung from profitable operations ($8.1M operating income) to substantial losses (-$10.3M), driven by an 85% spike in R&D expenses to $7.8M during a period of declining sales. The 69% drop in accounts receivable to $6.0M combined with 44% higher inventory levels suggests weakening demand and potential collection issues, though operating cash flow did improve to positive $528K.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+1011.1%
$27K→$300K

Share repurchases increased 1011.1% — management returning capital, signals confidence in intrinsic value.

Operating Income
P&L
-227.4%
$8.1M→-$10.3M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-216.1%
$6.6M→-$7.7M

Net income declined 216.1% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
+163.5%
-$831K→$528K

Operating cash flow surged 163.5% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
+84.5%
$4.2M→$7.8M

R&D investment increased 84.5% — signals commitment to future product development, though near-term margin impact.

Accounts Receivable
Balance Sheet
-69.4%
$19.7M→$6.0M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Gross Profit
P&L
-51.4%
$24.4M→$11.9M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Inventory
Balance Sheet
+44.2%
$10.1M→$14.6M

Inventory surged 44.2% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Revenue
P&L
-34.3%
$41.8M→$27.5M

Revenue declined 34.3% — significant demand weakness or market share loss warrants investigation.

Capital Expenditure
Cash Flow
-29%
$276K→$196K

Capex reduced 29% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

LANGUAGE CHANGES
NEW — 2026-03-04
PRIOR — 2025-03-05
ADDED
As of February 24, 2026, there were 16,462,059 shares of the registrant s common stock outstanding.
and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries, including ongoing geopolitical tensions between the U.S.
To date, geopolitical uncertainties other than those relating to China have not had any significant impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.
and Sensus Healthcare Services, LLC, unless the context otherwise indicates, Sensus, we, us, our, or the Company ) is a medical device company committed to providing highly effective, non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention.
To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions of close to one-million patients around the world.
+7 more — sign up free →
REMOVED
As of February 12, 2025, there were 16,495,396 shares of the registrant s common stock outstanding.
To date, the Middle East conflict, the Russian invasion of Ukraine, and other geopolitical uncertainties have not had any significant impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.
and Sensus Healthcare Services, LLC, unless the context otherwise indicates, Sensus, we, us, our, or the Company ) is a medical device company committed to providing highly effective, non-invasive, and cost-effective treatments for both oncological and non-oncological skin conditions.
To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in hundreds of thousands of patients around the world.
In February 2024, the Company formed Sensus Healthcare Services, LLC, a wholly-owned subsidiary that provides operational healthcare services to dermatology clinics.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →